Evidence map›Paper›PMID 36997505›Full record

ArticleNature communications2023

Turning universal O into rare Bombay type blood.

Itxaso Anso, Andreas Naegeli, Javier O Cifuente, Ane Orrantia, Erica Andersson, Olatz Zenarruzabeitia, Alicia Moraleda-Montoya, Mikel García-Alija, Francisco Corzana, Rafael A Del Orbe and 4 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
5.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Challenges in the Management of Hemorrhagic Shock in Patients with Bombay Blood Group in the ICU: What the H?Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Itxaso Anso *Structural Glycobiology Laboratory, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, 48903, Barakaldo, Bizkaia, Spain.ORCID 0000-0002-4106-8031
Andreas Naegeli *Genovis AB, Box 790, 22007, Lund, Sweden.
Javier O Cifuente *Structural Glycobiology Laboratory, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, 48903, Barakaldo, Bizkaia, Spain.ORCID 0000-0001-5420-121X
Ane OrrantiaImmunopathology Group, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, 48903, Barakaldo, Bizkaia, Spain.
Erica AnderssonGenovis AB, Box 790, 22007, Lund, Sweden.
Olatz ZenarruzabeitiaImmunopathology Group, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, 48903, Barakaldo, Bizkaia, Spain.
Alicia Moraleda-MontoyaStructural Glycobiology Laboratory, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, 48903, Barakaldo, Bizkaia, Spain.
Mikel García-AlijaStructural Glycobiology Laboratory, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, 48903, Barakaldo, Bizkaia, Spain.
Francisco CorzanaDepartamento Química and Centro de Investigación en Síntesis Quı́mica, Universidad de La Rioja, 26006, Logroño, Spain.ORCID 0000-0001-5597-8127
Rafael A Del OrbeHematology and Hemotherapy Service, Cruces University Hospital, Biocruces Bizkaia Health Research Institute, 48903, Barakaldo, Bizkaia, Spain.ORCID 0000-0002-1240-1958
Francisco BorregoImmunopathology Group, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, 48903, Barakaldo, Bizkaia, Spain.ORCID 0000-0002-3105-981X
Beatriz TrastoyStructural Glycobiology Laboratory, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, 48903, Barakaldo, Bizkaia, Spain. beatriz.trastoy@gmail.com.ORCID 0000-0002-2178-732X
Jonathan SjögrenGenovis AB, Box 790, 22007, Lund, Sweden. jonathan.sjogren@genovis.com.ORCID 0000-0003-1371-9623
Marcelo E GuerinStructural Glycobiology Laboratory, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, 48903, Barakaldo, Bizkaia, Spain. mrcguerin@gmail.com.ORCID 0000-0001-9524-3184
BioCruces Health research Institute · ESGenovis (Sweden) · SEIkerbasque · ESUniversidad de La Rioja · ES

Funding

Rationalizing glycoengineering strategies for immunotherapeutic antibodiesR01AI149297 · NIAID · EMORY UNIVERSITY · PI JEFFREY Victor RAVETCH, ERIC JOHN SUNDBERG · 2020 to 2026
$3.7M
NIAID NIH HHS R01 AI149297U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI149297
6 · The paper itself

Abstract

Red blood cell antigens play critical roles in blood transfusion since donor incompatibilities can be lethal. Recipients with the rare total deficiency in H antigen, the O

Indexed as

Blood TransfusionTransfusion ReactionABO Blood-Group SystemErythrocytesHumansPhenotypeABO Blood-Group System

Identifiers

PMID36997505
PMCPMC10063614
OpenAlexW4361273726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.